amiodarone has been researched along with Day Blindness in 18 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to describe a case of optic neuropathy after substitution of amiodarone with dronedarone for treatment of atrial fibrillation." | 7.96 | Case Report: Presumed Optic Neuropathy after Amiodarone and then Dronedarone for Treatment of Atrial Fibrillation. ( Maharshak, I; Paul, M; Steiner, H, 2020) |
| "Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs." | 7.66 | Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. ( Bhandari, A; Keung, E; Malone, P; Morady, F; Sauve, MJ; Scheinman, MM; Schwartz, AB; Shen, EN; Sung, RJ, 1983) |
| "Amiodarone hydrochloride is a potent antiarrhythmic agent recently approved for use by the Food and Drug Administration." | 5.29 | Progression of amiodarone induced cataracts. ( Dolan, BJ; Flach, AJ, 1993) |
| "Amiodarone is a benzofuran derivative used to treat cardiac arrhythmias." | 4.81 | Visual changes secondary to initiation of amiodarone: a case report and review involving ocular management in cardiac polypharmacy. ( Castells, DD; Teitelbaum, BA; Tresley, DJ, 2002) |
| "This study aimed to describe a case of optic neuropathy after substitution of amiodarone with dronedarone for treatment of atrial fibrillation." | 3.96 | Case Report: Presumed Optic Neuropathy after Amiodarone and then Dronedarone for Treatment of Atrial Fibrillation. ( Maharshak, I; Paul, M; Steiner, H, 2020) |
| "To assess the incidence of adverse effects associated with long-term amiodarone therapy, we reviewed the records of 217 consecutive patients who were treated for refractory arrhythmia." | 3.67 | Side effects and complications of amiodarone therapy. ( Lown, B; Podrid, PJ; Raeder, EA, 1985) |
| "Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs." | 3.66 | Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. ( Bhandari, A; Keung, E; Malone, P; Morady, F; Sauve, MJ; Scheinman, MM; Schwartz, AB; Shen, EN; Sung, RJ, 1983) |
| "Amiodarone's role as a cause of toxic optic neuropathy is based on case reports." | 2.73 | Absence of bilateral vision loss from amiodarone: a randomized trial. ( Anderson, J; Bardy, GH; Hellkamp, A; Johnson, G; Lee, KL; Mark, DB; Mindel, JS; Poole, JE, 2007) |
| "Amiodarone is an excellent antiarrhythmic medication; however, it has numerous systemic and ocular adverse effects." | 2.66 | Ocular Adverse Effects of Amiodarone: A Systematic Review of Case Reports. ( Alshehri, M; Joury, A, 2020) |
| "Numerous systemic drugs produce adverse effects that involve the eye." | 2.38 | Ocular side effects of selected systemic drugs. ( Jaanus, SD, 1992) |
| " After ruling out intracranial hypertension, arteritic ischemic optic neuropathy, non-arteritic, and inflammatory bilateral papilledema, the diagnosis was toxic optic neuropathy." | 1.51 | [Amiodarone-induced optic neuropathy: A rare side effect]. ( Ambrosi, P; Arcani, R; Arnould, T; Chagny, M; Daumas, A; Gayet, S; Gobin, N; Micallef, J; Pellerey, M; Rouby, F; Scapin, J; Villani, P, 2019) |
| " Many of these adverse side effects can be greatly reduced or prevented with close monitoring of patients." | 1.31 | Ocular toxicity of systemic medications: a case series. ( To, TQ; Townsend, JC, 2000) |
| "Amiodarone hydrochloride is a potent antiarrhythmic agent recently approved for use by the Food and Drug Administration." | 1.29 | Progression of amiodarone induced cataracts. ( Dolan, BJ; Flach, AJ, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (27.78) | 18.7374 |
| 1990's | 3 (16.67) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 2 (11.11) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Arcani, R | 1 |
| Pellerey, M | 1 |
| Rouby, F | 1 |
| Gobin, N | 1 |
| Scapin, J | 1 |
| Chagny, M | 1 |
| Arnould, T | 1 |
| Ambrosi, P | 1 |
| Gayet, S | 1 |
| Micallef, J | 1 |
| Villani, P | 1 |
| Daumas, A | 1 |
| Alshehri, M | 1 |
| Joury, A | 1 |
| Maharshak, I | 1 |
| Paul, M | 1 |
| Steiner, H | 1 |
| Le-Nguyen, XT | 1 |
| Lee, TK | 1 |
| Do, DV | 1 |
| Sepah, YJ | 1 |
| Nguyen, QD | 1 |
| Rao, NA | 1 |
| Vasconcelos-Santos, DV | 1 |
| Goldstein, DA | 1 |
| Castells, DD | 1 |
| Teitelbaum, BA | 1 |
| Tresley, DJ | 1 |
| Domingues, MF | 1 |
| Barros, H | 1 |
| Falcão-Reis, FM | 1 |
| Enseleit, F | 1 |
| Wyss, CA | 1 |
| Duru, F | 1 |
| Noll, G | 1 |
| Ruschitzka, F | 1 |
| Mindel, JS | 1 |
| Anderson, J | 1 |
| Hellkamp, A | 1 |
| Johnson, G | 1 |
| Poole, JE | 1 |
| Mark, DB | 1 |
| Lee, KL | 1 |
| Bardy, GH | 1 |
| Ingram, DV | 1 |
| Harris, L | 1 |
| McKenna, WJ | 1 |
| Rowland, E | 1 |
| Krikler, DM | 1 |
| Morady, F | 1 |
| Sauve, MJ | 1 |
| Malone, P | 1 |
| Shen, EN | 1 |
| Schwartz, AB | 1 |
| Bhandari, A | 1 |
| Keung, E | 1 |
| Sung, RJ | 1 |
| Scheinman, MM | 1 |
| Onofrey, BE | 1 |
| Jones, WL | 1 |
| Magnus, DE | 1 |
| Flach, AJ | 1 |
| Dolan, BJ | 1 |
| Hara, M | 1 |
| Matsumori, A | 1 |
| To, TQ | 1 |
| Townsend, JC | 1 |
| Speicher, MA | 1 |
| Goldman, MH | 1 |
| Chrousos, GA | 1 |
| Jaanus, SD | 1 |
| Raeder, EA | 1 |
| Podrid, PJ | 1 |
| Lown, B | 1 |
3 reviews available for amiodarone and Day Blindness
| Article | Year |
|---|---|
Ocular Adverse Effects of Amiodarone: A Systematic Review of Case Reports.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Case-Control Studies; Corneal Diseases; | 2020 |
Visual changes secondary to initiation of amiodarone: a case report and review involving ocular management in cardiac polypharmacy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Male; Polypharmacy; Vision D | 2002 |
Ocular side effects of selected systemic drugs.
Topics: Amiodarone; Anti-Inflammatory Agents; Antirheumatic Agents; Chloroquine; Chlorpromazine; Drug Intera | 1992 |
1 trial available for amiodarone and Day Blindness
| Article | Year |
|---|---|
Absence of bilateral vision loss from amiodarone: a randomized trial.
Topics: Amiodarone; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up | 2007 |
14 other studies available for amiodarone and Day Blindness
| Article | Year |
|---|---|
[Amiodarone-induced optic neuropathy: A rare side effect].
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Iatrogenic Disease; Optic Ner | 2019 |
Case Report: Presumed Optic Neuropathy after Amiodarone and then Dronedarone for Treatment of Atrial Fibrillation.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Substi | 2020 |
Diagnostic and therapeutic challenges.
Topics: Adult; Amiodarone; Central Nervous System Diseases; Diagnosis, Differential; Glucocorticoids; Humans | 2011 |
Amiodarone and optic neuropathy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Case-Control Studies; Contrast Sensitivity; Evoked Potenti | 2004 |
Images in cardiovascular medicine. The blue man: amiodarone-induced skin discoloration.
Topics: Amiodarone; Atrial Fibrillation; Humans; Male; Middle Aged; Pigmentation Disorders; Skin Pigmentatio | 2006 |
Ocular effects in long-term amiodarone therapy.
Topics: Amiodarone; Benzofurans; Corneal Diseases; Eye Diseases; Humans; Vision Disorders | 1983 |
Side effects and possible contraindications of amiodarone use.
Topics: Aged; Alanine Transaminase; Amiodarone; Aspartate Aminotransferases; Benzofurans; Corneal Diseases; | 1983 |
Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.
Topics: Aged; Amiodarone; Anorexia; Ataxia; Benzofurans; Female; Heart Arrest; Humans; Lung Diseases; Male; | 1983 |
Amiodarone-induced cutaneous and corneal pigment deposits.
Topics: Amiodarone; Benzofurans; Corneal Diseases; Humans; Male; Middle Aged; Pigmentation Disorders; Vision | 1984 |
Progression of amiodarone induced cataracts.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Cataract; Contrast Sensitivity; Follow-Up Studies; Humans; L | 1993 |
[Impaired left ventricular function in a patient with visual disturbance].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopathies; Female; Humans; Sa | 1998 |
Ocular toxicity of systemic medications: a case series.
Topics: Adult; Aged; Amiodarone; Cataract; Corneal Diseases; Eye Diseases; Female; Glaucoma; Humans; Isoniaz | 2000 |
Amiodarone optic neuropathy without disc edema.
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Male; Middle Aged; Optic Nerve; Optic Nerve Diseases; Pa | 2000 |
Side effects and complications of amiodarone therapy.
Topics: Amiodarone; Arrhythmias, Cardiac; Ataxia; Benzofurans; Drug Eruptions; Drug Interactions; Female; Ga | 1985 |